Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How Aspirin Does More Than Kill Pain

By Drug Discovery Trends Editor | April 1, 2016

“I think aspirin is the best anticancer drug today. I think everyone over 50 should take aspirin. It’s the cheapest thing on the planet and very effective… I take one pill of 25 mg a day.” So said Professor Mel Greaves of the Institute of Cancer Research in London at a recent conference where he was presenting a paper on the complexities of cancer.

Aspirin is a classic anti-inflammatory drug. It inhibits the production of an enzyme involved in driving inflammation. (It also inhibits the action of a closely related enzyme, potentially causing the side-effect of gastric bleeding.)

There is research in animals and people suggesting that long-term consumption of aspirin can reduce the risk of developing various cancers, or of certain cancers coming back. Whether or not it should be taken routinely as a prophylactic is hotly debated, partly because of the side-effects. But, in October 2015, a new trial got underway in the UK: it is the world’s biggest clinical trial to date to investigate whether aspirin really can prevent bowel, breast, prostate, stomach and oesophageal cancer returning in people who have been successfully treated. If successful, it will determine whether for this group, at least, the benefits outweigh the risks.

This article originally appeared on Mosaic. You can read the rest of the story here.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE